{"url_path":"/sec/vxrt/8-k/2026-06-26/item-1-01","section_key":"item-1-01","section_title":"Item 1.01 **           **Entry into a Material Definitive Agreement.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-26","source_url":"https://www.sec.gov/Archives/edgar/data/72444/0001437749-26-021833-index.html","accession_number":"0001437749-26-021833","cik":"0000072444","ticker":"VXRT","issuer_name":"Vaxart, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/72444/0001437749-26-021833-index.html","primary_entity_key":"0000072444","primary_entity_name":"Vaxart, Inc."},"word_count":262,"has_tables":true,"body_markdown":"**Item 1.01**           **Entry into a Material Definitive Agreement.**\n\n \n\nOn June 22, 2026, Vaxart, Inc. (the “Company”) entered into Modification No. 7 (the “Modification”) to the ATI-RRPV Project Award Agreement No. 001, dated June 13, 2024 (the “Project Agreement”), with Advanced Technology International, the Rapid Response Partnership Vehicle’s Consortium Management Firm funded by the Biomedical Advanced Research and Development Authority (“BARDA”) of the U.S. Department of Health and Human Services. As previously disclosed, pursuant to the Project Agreement, the Company received funding to conduct a Phase 2b comparative study (the “Trial”) evaluating the Company’s oral pill COVID-19 vaccine candidate against an mRNA vaccine comparator approved by the U.S. Food and Drug Administration.\n\n \n\nPursuant to the Modification, the total amount of funding available for payment under the Project Agreement is approximately $345 million (a decrease of approximately $116 million from the prior modification), following an approximately 50% reduction in participants enrolled in the trial as the result of a BARDA partial termination ordered on August 5, 2025. The approximately $345 million of funding available includes approximately $68 million of firm fixed price amounts and the remaining amount for reimbursement of costs incurred in trial preparation and execution activities. In addition, the Modification allows for the release of approximately $29 million for completion of the trial and exploratory analyses to further evaluate safety and efficacy.\n\n \n\nThe foregoing description of the Modification does not purport to be complete and is qualified in its entirety by reference to the full text of the Modification, which will be filed as an exhibit to the Company’s next periodic report."}